SCHEMBL19686493

SCHEMBL19686493

COc1nn(-c2nc(NC3CCC(F)(F)CC3)cc(N3CCOCC3)n2)cc1F

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EHMT2 Q96KQ7 4/20 0.37
EHMT1 Q9H9B1 4/20 0.37
GAA P10253 3/20 0.36
KDM4E B2RXH2 7/20 0.36
ALDH1A1 P00352 4/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
THRB P10828 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
MAPT P10636 5/20 0.35
LMNA P02545 4/20 0.35
APAF1 O14727 1/20 0.35
PIK3CA P42336 2/20 0.35
ADORA2A P29274 1/20 0.35
ADORA1 P30542 1/20 0.35
LRRK2 Q5S007 2/20 0.35
NSD2 O96028 1/20 0.34
POLB P06746 1/20 0.34
MAPK1 P28482 1/20 0.34
MPI P34949 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19687094 0.88 PDE10A (0.39) GAAKDM4EALDH1A1MEN1KMT2A
SCHEMBL19686707 0.83 IDH1 (0.41) EHMT2EHMT1GAAKDM4EALDH1A1
SCHEMBL19686339 0.82 KDM4E (0.38) GAAKDM4EALDH1A1MEN1KMT2A
SCHEMBL21165915 0.81 ADORA2A (0.40) GAAKDM4EALDH1A1MEN1KMT2A
SCHEMBL19686447 0.81 IDH1 (0.46) GAAKDM4EALDH1A1MEN1KMT2A
SCHEMBL19687055 0.81 IDH1 (0.44) GAAKDM4EALDH1A1MEN1KMT2A
SCHEMBL19687234 0.80 ADORA2A (0.39) GAAKDM4EALDH1A1MEN1KMT2A
Rimtuzalcap SCHEMBL19686931 0.80 IDH1 (0.43) GAAKDM4EALDH1A1MEN1KMT2A
Rimtuzalcap SCHEMBL29920754 0.80 IDH1 (0.43) GAAKDM4EALDH1A1MEN1KMT2A
SCHEMBL21143989 0.80 ADORA2A (0.38) GAAKDM4EALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 US disclosed
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2019-07-18 US disclosed
WO-2017139697-A9 BACTERIA ENGINEERED TO TREAT DISEASES ASSOCIATED WITH HYPERAMMONEMIA SYNLOGIC, INC. (US) 2017-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10774064-B2 Potassium channel modulators KCNJ11, KCNJ2, KCNJ1 EHMT2 3277/4885EHMT1 2638/4885GAA 1172/4885
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 EHMT2 3277/4885EHMT1 2638/4885GAA 1172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.